Palatin Technologies, Inc.  

(Public, NYSEMKT:PTN)   Watch this stock  
Find more results for PTN
-0.010 (-2.63%)
May 26 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.37 - 0.38
52 week 0.29 - 0.90
Open 0.38
Vol / Avg. 1.06M/2.71M
Mkt cap 55.05M
P/E     -
Div/yield     -
EPS -0.24
Shares 152.80M
Beta 1.33
Inst. own 15%
May 18, 2017
Q3 2017 Palatin Technologies Inc Earnings Release (Estimated)
May 16, 2017
Q3 2017 Palatin Technologies Inc Earnings Call - Webcast
Apr 4, 2017
Palatin Technologies, Inc. Presents at The MicroCap Conference New York, Apr-04-2017 01:00 PM
Mar 14, 2017
Palatin Technologies Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -32.93% -
Operating margin -27.83% -
EBITD margin - -
Return on average assets -37.75% -256.43%
Return on average equity - -
Employees 22 -
CDP Score - -


4B Cedarbrook Dr
CRANBURY, NJ 08512-3641
United States - Map
+1-609-4952200 (Phone)
+1-609-4952202 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company's primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. Its other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). MC4r is a compound used for treatment of obesity and diabetes. PL-3994 is a subcutaneously injected guanylate-cyclase type A (GC-A) receptor agonist. MC1r agonist peptides are used for treatment of inflammatory and dermatologic disease indications.

Officers and directors

John K. A. Prendergast Ph.D. Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Carl Spana Ph.D. President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Stephen T. Wills CPA Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary
Age: 59
Bio & Compensation  - Reuters
Robert K. deVeer Jr. Independent Director
Age: 70
Bio & Compensation  - Reuters
Alan William Dunton M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Zola P. Horovitz Ph.D. Independent Director
Age: 80
Bio & Compensation  - Reuters
J. Stanley Hull Independent Director
Age: 63
Bio & Compensation  - Reuters
Arlene M. Morris Independent Director
Age: 64
Bio & Compensation  - Reuters